Latest updates for Atmp

Fresh curated links around ATMP are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Recent items include:

  • Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
  • RMTG's Cellgenic Division Launches Natural Killer (NK) Cell Product Line for International Markets
  • Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Post angles to try

Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

newswire.com /4 weeks ago

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Figh...

Read source
newswire.com /1 month ago

RMTG's Cellgenic Division Launches Natural Killer (NK) Cell Product Line for International Markets

New NK cell platform extends RMTG's cellular-technology portfolio into immunology-adjacent applications, with an initial commercial focus on Latin America and Southeast Asia.

Read source
newswire.com /1 month ago

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success

Read source
genengnews.com /4 weeks ago

Altruist Biologics’ Suzhou Site Receives EMA GMP Certification

The company’s Quality Risk Management framework enabled proactive identification of compliance risks, reduced uncertainties associated with cross-regional technology transfer, and...

Read source
orthotw.com /2 weeks ago

PearlMatrix® P-15 Peptide Enhanced Bone Graft Receives Medicare New Technology Add-on Payment (NTAP), Helping Hospitals...

NTAP provides additional Medicare reimbursement to hospitals using PearlMatrix, the first and only bone growth accelerator demonstrating superior lumbar fusion speed.

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Start creating posts

Sources covering Atmp

feeds.feedburner.com

Recent coverage from public sources
Public source

ryortho.com

Recent coverage from public sources
Public source

newswire.com

Recent coverage from public sources
Public source

Related searches

Bioprocessing Legal & Regulatory and Reimbursement News Topics

Recent searches

Artificial Intelligence Machine Learning Data Science Data Engineering Business Intelligence Web Development Software Development Software Testing Programming JavaScript DevOps Cyber Security Product Management Project Management Design UX UX Research Graphic Design Video Production Video Editing